COP vs STRO
ConocoPhillips (COP) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the COP and STRO stock pages for the full models.
Not investment advice.